Physician profile
Joy E Inyang
NPI 1851373393
$1,134.87
in general payments reported to CMS, 2019-2025
11 companies · $106 in 2025
The $106 reported for 2025 was more than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.88 · 2020: $15.50 · 2021: $82.21 · 2022: $149 · 2023: $387 · 2024: $353 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $384.55 | 2019-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Corium, LLC | $216.45 | 2023-2025 | Azstarys |
| Cranial Technologies, INC | $168.06 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $115.71 | 2021-2024 | Bexsero, Pediarix, Rotarix |
| Sobi, INC | $106.50 | 2021-2023 | |
| Pfizer INC. | $39.94 | 2023-2024 | |
| Supernus Pharmaceuticals, INC. | $33.56 | 2024 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $24.07 | 2024 | Flumist Quadrivalent |
| Sanofi Pasteur INC. | $17.66 | 2023 | |
| Seqirus USA INC | $14.90 | 2022 | |
| Ironshore Pharmaceuticals INC. | $13.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Inyang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.